A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer

A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer
复制标题

全反式维A酸诱导分化治疗晚期甲状腺癌的临床研究

DOI:
10.1097/mnm.0b013e3280708ebf
复制
发表时间:
2007-04
影响因子:
1.5
通讯作者:
Zhang, Yifan
Zhang, Yifan
中科院分区:
医学4区
文献类型:
--
作者:
Wang, Zhaohui;Liu, Yong;Zhu, Chengmo;Lu, Hui;Jia, Shiquan;Li, Biao;Zhang, Yifan

文献摘要

参考文献

相似文献

目的评价全反式维甲酸(ATRA)治疗去分化甲状腺癌患者分化标志物的变化及治疗效果。方法对2001年9月至2004年7月收治的11例患者进行回顾性分析。他们患有去分化甲状腺癌(DTC)(四个滤泡性癌、五个乳头状癌、两个嗜氧性癌),并被选择接受 ATRA(1.00±0.09 mg · kg−1 · d−1)治疗 30 或 60 天。所有患者均患有晚期肿瘤,并接受过手术和放射性碘治疗。广泛的肿瘤侵袭、远处转移扩散以及放射性碘吸收不足或不存在,排除了传统的治疗选择。测量并比较这些患者在 ATRA 治疗前后 131I 摄取、靶病灶反应和血清甲状腺球蛋白 (Tg) 水平的变化。结果 11 例 DTC 患者中,4 例碘摄入量增加,5 例目标病灶出现部分缓解 (PR),2 例病情稳定。对 8 名患者的 Tg 进行了评估,其中两名应答者表现出放射性碘摄取增加或无变化,Tg 水平降低,以及 ATRA 诱导分化治疗后的 PR。结论ATRA对DTC的分化状态有影响,值得进一步研究。
ObjectiveTo evaluate the changes in differentiation markers and therapeutic effects in all-trans-retinoic acid (ATRA)-treated patients with dedifferentiated thyroid cancer. MethodsBetween September 2001 and July 2004 eleven patients were analysed retrospectively. They had dedifferentiated thyroid cancers (DTC) (four follicular, five papillary, two oxyphilic) and were selected for treatment with ATRA (1.00±0.09 mg · kg−1 · d−1) for 30 or 60 days. All patients had advanced stage tumours with prior operative and radioiodine treatment. Extensive tumour invasion, distant metastatic spread, and insufficient or non-existent uptake of radioiodine precluded conventional therapeutic options. Changes in 131I uptake, response of target lesions, and serum thyroglobulin (Tg) levels were measured and compared in these patients before and after ATRA therapy. ResultsIn 11 patients with DTC, iodine uptake was increased in four and there was a partial response (PR) of target lesions in five patients as well as two patients with stable disease. Tg was assessed in eight patients, in whom two responders showed increased radioiodine uptake or no change and decreased Tg level, as well as PR after ATRA-induced differentiation therapy. ConclusionsATRA has an effect on the differentiation status of DTC and deserves further investigation.
DOI: 10.1182/blood.v76.9.1704.bloodjournal7691704
发表时间: 1990-11
期刊: Blood
影响因子: 20.3
作者:
S. Castaigne;C. Chomienne;Danielson Mt;P. Ballerini;R. Berger;P. Fenaux;L. Degos
通讯作者: S. Castaigne;C. Chomienne;Danielson Mt;P. Ballerini;R. Berger;P. Fenaux;L. Degos
DOI: 10.1096/fasebj.10.9.8801174
发表时间: 1996-07
期刊: The FASEB Journal
影响因子: --
作者:
G. Wolf
通讯作者: G. Wolf
DOI: 10.1038/sj.onc.1202543
发表时间: 1999-04-08
期刊: ONCOGENE
影响因子: 8
作者:
Sun, SY;Yue, P;Lotan, R
通讯作者: Lotan, R
DOI: 10.1210/mend.11.9.9977
发表时间: 1997-08
影响因子: --
作者:
C. Teixeira;M. A. Christine Pratt
通讯作者: C. Teixeira;M. A. Christine Pratt